Drug Trial Radar · NCT01963208
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
Last checked: Nov 19, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Oct 2013
Primary completion
May 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- Marinus PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 16, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
Conditions
- Drug Resistant Partial Onset Seizure
Interventions
ganaxoloneDrug
200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
PlaceboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance PeriodTime frame: Baseline and Week 14
Locations
71 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama Epilepsy Center
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Xenoscience Inc.
Phoenix, Arizona
The MORE Foundation
Sun City, Arizona
Clinical Trials Inc.
Little Rock, Arkansas
Neuro-Pain Medical Center, Inc
Fresno, California
Neurological Research Institute
Santa Monica, California
University of Colorado- Anschutz Outpatient Pavilion
Aurora, Colorado
Neuroscience Consulants
Miami, Florida
Medsol Clinical Research Center
Port Charlotte, Florida
Consultants in Epilepsy & Neurology
Boise, Idaho
Bluegrass Epilepsy Research, LLC
Lexington, Kentucky
Mid-Atlantic Epilepsy Center
Bethesda, Maryland
Bringham and Women's Hospital
Boston, Massachusetts
Minneapolis Clinic of Neurology
Golden Valley, Minnesota
The Comprehensive Epilepsy Care Center for Children and Adults
Chesterfield, Missouri
Cooper Medical Center of Rowan University
Camden, New Jersey
Northeast Regional Epilepsy Group
Hackensack, New Jersey
Five Towns Neuroscience Research
Cedarhurst, New York
Northeast Regional Epilepsy Group
Middletown, New York
Winthrop University Hospital
Mineola, New York
New York University Comprehensive Epilepsy Center
New York, New York
Northeast Regional Epilepsy Group
New York, New York
Wake Forest Health Sciences
Winston-Salem, North Carolina
Ohio Clinical Research Partners, LLC
Canton, Ohio
Ohio State University
Columbus, Ohio
Lynn Health Institute
Oklahoma City, Oklahoma
Sooner Clinical Research
Oklahoma City, Oklahoma
Jefferson Comprehensive Epilepsy Center
Philadelphia, Pennsylvania
Temple University School of Medicine
Philadelphia, Pennsylvania
Neurology Consultants of Dallas
Dallas, Texas
Texas Epilepsy Group
Dallas, Texas
Rainier Clinical Research Center, Inc.
Renton, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
The Prince of Wales Hospital
Randwick, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Flinders Medical Center
Bedford Park, South Australia, Australia
St. Vincent's Hospital
Fitzroy, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health
Heidelberg, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.